Venetoclax is a Bcl-2 inhibitor approved in USA for CLL patients with 17p deletion, and in Europe for those who failed or do not tolerate BCR inhibitors. Here, Jennifer Brown, MD, PhD from Dana-Farber Cancer Institute, Boston, MA discusses the results presented at ASH 2017 on the MURANO trial, where venetoclax has been tested in combination with rituximab versus bendamustine plus rituximab. This video was recorded at the American Society of Hematology Annual Meeting 2017, held in Atlanta, GA.

свернуть